Jinan

Researchers are evaluating PM8002, a bispecific antibody that targets PD-L1 and VEGF-A, as a single treatment in adults with advanced solid tumors. This Phase Ib/IIa study aims to understand the safety, tolerability, how the drug moves and acts in the body, immune response, and anti-tumor effects of PM8002 in this patient group. The study focuses on patients with malignant tumors confirmed by tissue analysis who have not fully recovered from previous anti-tumor treatments. Participants will receive PM8002 through intravenous infusion. The study does not mention comparator groups, focusing on the effects of this single agent. Treatment monitoring includes evaluating dose-limiting toxicities during the first three weeks of therapy. The treatment period is followed by safety monitoring for adverse events up to 30 days after the last dose. Participants will be observed for objective tumor response for up to approximately two years. Throughout the study, participants will undergo various assessments including safety evaluations, pharmacokinetic and pharmacodynamic tests, and immunogenicity measurements. Researchers will track adverse events and tumor responses based on RECIST 1.1 criteria, requiring at least one measurable lesion. Participants must have an ECOG performance status of 0-1 and an expected survival of at least 12 weeks. The overall study duration includes treatment and long-term follow-up to evaluate the drug's safety and effectiveness.